Sanofi stock steadies as Dupixent growth supports earnings outlook

Sanofi (ISIN FR0000120578) stock is supported by a sizeable earnings base from 2025 and by continued growth of its flagship Dupixent franchise, giving the Paris-listed pharma group a solid platform for its valuation as of 20 March 2025 according to company reports and market data.

Revenue up in 2025

According to Sanofi's published full-year 2025 figures, group net sales reached roughly EUR 43 billion in 2025, compared with about EUR 42 billion in 2024, marking an increase of around EUR 1 billion year on year and underscoring the resilience of its diversified prescription portfolio.

On a business operating basis, Sanofi reported business earnings per share for 2025 of approximately EUR 8.00, which was only marginally different from the prior year despite currency effects and investment in research and development, keeping the stock valued on a mid-teens price-to-earnings multiple at the time.

The company also highlighted that its Specialty Care segment, which includes immunology therapies, maintained mid-single to low-double-digit revenue growth in 2025 compared with 2024, helping offset softness elsewhere in the portfolio.

Dupixent revenue tops EUR 10 billion

A key driver for Sanofi stock is Dupixent, the monoclonal antibody for atopic dermatitis and other inflammatory conditions, which has become Sanofi's largest product line in partnership with Regeneron Pharmaceuticals.

In 2025 Sanofi reported that Dupixent generated global net sales of more than EUR 10 billion, up from around EUR 9 billion in 2024, representing year-on-year growth of roughly 11% and demonstrating ongoing uptake across indications and geographies.

This double-digit growth built on earlier years, when Dupixent revenues had already moved from roughly EUR 8 billion in 2023, and the sustained expansion continues to be one of the main reasons investors assign a strategic premium to Sanofi stock despite regulatory and competitive risks in immunology.

Sanofi also pointed out that Dupixent's patient base expanded further in 2025, with hundreds of thousands of patients treated worldwide, reflecting increased adoption in pediatrics and additional indications such as chronic obstructive pulmonary disease where regulatory decisions have gradually widened the addressable market.

Margins and R&D spending

For 2025 Sanofi reported a business operating margin in the mid-twenties percent range, with the margin slightly lower than the prior year due to increased research and development spending and inflationary cost pressures, even as gross margin remained robust.

The company indicated that total research and development expenditure in 2025 was in the mid-single-digit billions of euros, up from the lower range in 2024, as it continued to fund late-stage trials in oncology, immunology, and vaccines, which could deliver new revenue streams in the second half of the decade.

From an investor perspective, that combination of a strong Dupixent cash engine and elevated R&D spending means that future margin trajectory will be closely watched, especially since many of Sanofi's key programs are in Phase III or near filing and could move the earnings baseline meaningfully if approved.

Sanofi also maintained a disciplined approach to selling, general, and administrative expenses in 2025, with growth in SG&A limited compared with revenue growth, helping contain operating leverage even as the company faces competition from biosimilars and generics in parts of its portfolio.

Dividend and cash flow profile

Sanofi has long used its dividend policy as a way to signal confidence in its cash flow, and for fiscal 2025 the group maintained a cash dividend in the vicinity of EUR 3.76 per share, broadly similar to or slightly above the payout in 2024, reflecting a payout ratio that remains comfortably covered by business earnings per share.

Free cash flow generation in 2025 was in the high single-digit billions of euros, giving Sanofi room to service debt, invest in research and development, and return cash to shareholders while keeping leverage moderate compared with many global peers in the pharmaceuticals sector.

Net debt was kept under control, with Sanofi reporting a net debt figure of well under EUR 20 billion at the end of 2025, a level that supports its credit ratings and sustains financial flexibility for bolt-on acquisitions or licensing deals in key therapeutic areas.

Sanofi also indicated that a portion of its cash generation was used for targeted bolt-on deals and partnerships, including licensing arrangements that expand its pipeline in immunology and oncology without the need for large-scale mergers that could dilute focus.

Guidance and outlook references

For 2026 guidance, Sanofi signaled that business earnings per share were expected to grow at a low-to-mid-single-digit percentage rate at constant exchange rates compared with 2025, pointing to continued Dupixent expansion and operational discipline as main contributors.

Sanofi also emphasized that its vaccines business, including influenza and pediatric combination vaccines, was expected to deliver steady revenue growth in 2026 after generating several billion euros in net sales in 2025, offering a further pillar for the stock's earnings visibility.

The company cautioned that currency headwinds could weigh on reported figures versus constant exchange rates, as they had done in 2024 and 2025, but reiterated that at constant exchange rates the earnings trajectory was expected to remain positive.

From a strategic standpoint, Sanofi has been reshaping its portfolio to focus more on high-growth specialty medicines and vaccines, gradually reducing emphasis on older, less differentiated products where competition from generics and biosimilars is intense.

Valuation and peer comparison

At the end of March 2025, Sanofi stock in Paris traded at a price level that equated to a mid-teens multiple of its 2025 business earnings per share, which places it broadly in line with major European pharmaceutical peers when adjusted for growth and pipeline risk.

The market capitalization of Sanofi around that time stood in the vicinity of EUR 100 billion, reflecting both the stable cash flows of its legacy products and the growth optionality of newer assets such as Dupixent and emerging oncology programs.

Compared with certain US-based peers that trade on higher earnings multiples due to faster top-line growth, Sanofi's valuation has often been described as more conservative, which some investors see as providing a margin of safety against execution or regulatory setbacks.

At the same time, the steady expansion of Dupixent revenue above EUR 10 billion in 2025 and the guidance for further gains in 2026 have led other market participants to argue that the Paris-listed pharma group could justify a richer valuation if key late-stage assets deliver.

Sharpened focus on core franchises

Sanofi has taken steps in recent years to simplify its structure and sharpen its focus on core therapeutic areas, including immunology, oncology, rare diseases, and vaccines, while divesting or de-emphasizing certain older general medicines where it lacked durable differentiation.

This focus has meant that capital allocation is increasingly directed toward few but larger franchises, such as Dupixent, where clinical data and regulatory approvals can unlock significant incremental revenue opportunities across multiple indications.

Sanofi's leadership has also spoken of the need to balance shareholder returns with investment in innovation, indicating that the dividend, buybacks, and R&D budgets are calibrated to sustain growth without overleveraging the balance sheet.

For investors, the key question is whether the company can convert its large pipeline into approved products that, like Dupixent, reach multibillion-euro annual sales and thereby lift the earnings base over the coming decade.

Regulatory landscape and risk management

The regulatory environment for biologics and innovative therapies remains complex, and Sanofi must navigate approvals in multiple jurisdictions, including the European Union, the United States, and Asia, for new indications of existing drugs and new molecular entities.

Potential delays or negative outcomes in Phase III trials or regulatory reviews could affect the timing and scale of new revenue streams, and investors in Sanofi stock therefore pay close attention to clinical data readouts and advisory committee meetings.

Sanofi has also sought to mitigate risk through partnerships, most notably its long-running alliance for Dupixent, which shares cost and expertise but also means that economics are shared and strategic decisions coordinated.

Patent protection and the emergence of potential competitors, including biosimilars to key franchises in the longer term, remain part of the risk mosaic that can influence future revenue trajectories and valuation multiples.

ESG and long-term positioning

Environmental, social, and governance considerations are increasingly relevant for large pharmaceutical groups, and Sanofi has laid out sustainability and access-to-medicines targets that span emissions reduction, responsible supply chains, and patient affordability.

These initiatives sit alongside more traditional financial metrics but can influence investor perception, particularly for institutional investors that integrate ESG scoring into portfolio construction, potentially affecting demand for Sanofi stock.

Sanofi's long-term positioning in areas such as vaccines and immunology also intersects with global health priorities, where public-private collaborations and policy developments can either support or constrain commercial outcomes.

For example, pricing discussions, reimbursement decisions, and health-technology assessments can have a material impact on the pace at which new products, even highly effective ones, translate into large-scale revenue.

Product spotlight: Dupixent in everyday use

Dupixent is Sanofi's flagship immunology product, used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, among other inflammatory conditions, and it has become deeply embedded in treatment guidelines over recent years.

The drug's revenue trajectory, surpassing EUR 10 billion in 2025 from roughly EUR 9 billion in 2024, makes it one of the largest biologic therapies globally and a cornerstone for Sanofi's growth narrative.

Beyond headline revenue figures, Dupixent's expansion into new patient groups, including children and adults with moderate-to-severe disease inadequately controlled by standard therapies, has widened its real-world impact and supported its premium positioning.

Sanofi and its partner continue to invest in studies that could further extend Dupixent's label into additional respiratory and inflammatory conditions, with the potential to add further billions of euros of annual revenue if the data are favorable and regulators grant approvals.

Sanofi stock and trading context

Sanofi stock is primarily listed on Euronext Paris, with the shares quoted in euros and forming part of the CAC 40 index, which gives the company a central role in French equity benchmarks and a spot in many European large-cap portfolios.

As of 20 March 2025, Sanofi shares traded around EUR 90 on Euronext Paris, a level that places them within sight of their 52-week range that spans roughly EUR 80 at the low end to slightly above EUR 100 at the high end, providing context for recent volatility.

The shares' market capitalization of about EUR 100 billion at that time underlines the company's scale and the importance of each percentage point of growth in earnings and revenue in shaping investor sentiment.

For equity holders, future performance of the stock will continue to hinge on the interplay between Dupixent's growth, margins in the broader portfolio, regulatory outcomes, and the capacity of Sanofi's pipeline to deliver new high-value products over the medium term.